Investors

Unique Platform

We believe that our proprietary continuous drug delivery technology could lead to NEW therapies with profound safety and efficacy benefits.

IP Portfolio

4 USPTO Patent Applications filed
4 PCT Patent Applications filed
1 Provisional Application filed

Experienced Team

Pike’s Management, Advisors, and Transdermal Lab, bring together decades of experience in Capital Markets, Pharma Development, IP Strategy, Transdermal Formulation, Regulatory Strategy and Clinical Trial Design and Management.

1 million
People living with Parkinson’s Disease in the U.S.

Parkinson’s Foundation

US$52bn
The estimated combined direct and indirect cost of Parkinson’s in the U.S.

Parkinson’s Foundation

51.5m (20.6%)
US. adults that experienced mental illness in 2019

NAMI National Alliance on Mental Illness

US$15bn
Estimated value of the U.S. Antidepressant market by 2025

Brandessence Market Research